Latest News
Prexton begins Phase II trial of Foliglurax to treat Parkinson’s disease
Swiss biopharmaceutical firm Prexton Therapeutics has begun a Phase II clinical trial (AMBLED) of Foliglurax for the treatment of patients suffering with Parkinson’s disease...
Alnylam and Sanofi commence Phase III programme for haemophilia drug
Alnylam Pharmaceuticals and Sanofi Genzyme have commenced the Phase III clinical programme (ATLAS) of RNAi therapeutic fitusiran in patients with haemophilia A or B, with or without...
Exelixis and BMS start Phase III combination trial for renal cell carcinoma
Inotek’s trabodenoson shows no clinical advantage in Phase II FDC trial for glaucoma
Trovagene selects PRA Health Sciences to conduct Phase lb/ll trial of PCM-075 for AML
US-based biotechnology company Trovagene has chosen global contract research organisation (CRO) PRA Health Sciences to carry out its Phase lb/ll clinical trial of PCM-075, a polo-like kinase...
BeiGene commences dosing in Phase II trial of BGB-A317 to treat urothelial cancer
Global biotechnology company BeiGene has commenced dosing patients in a new Phase II trial of its investigational anti-PD-1 antibody, BGB-A317, in patients with urothelial cancer (UC),...
Ferring reports positive outcome from Phase III trials of fertility drug
Galapagos and Gilead commence Phase II trial of filgotinib for uveitis
Belgian biotechnology firm Galapagos and its collaboration partner Gilead Sciences has commenced a Phase II clinical trial of filgotinib to treat patients suffering from...
Aimmune begins patient enrolment in European Phase lll trial of AR101 for peanut allergy
US-based Aimmune Therapeutics has begun enrolling patients for the European Phase lll ARTEMIS (ARC010) clinical trial of its investigational biologic oral immunotherapy, AR101, to treat...
Boehringer reports positive safety profile of Jardiance for type 2 diabetes
Boehringer Ingelheim has reported a positive safety profile of oral Jardiance (empagliflozin) for the treatment of adults with type 2...
BrainStorm chooses Worldwide as CRO for Phase III ALS trial
Noxxon Pharma starts dosing in Phase I/II trial of NOX-A12 for cancer
German firm Noxxon Pharma has started dosing patients in a Phase I/II clinical trial of NOX-A12 (olaptesed pegol) in combination with Keytruda (pembrolizumab) to treat metastatic colorectal...
Oxford University to investigate AZD1775 for bowel cancer
Zealand starts enrolment in Phase III trial of dasiglucagon for hypoglycemia
Denmark-based biotechnology firm Zealand Pharma has started patient enrolment in Phase III clinical trial of dasiglucagon to treat severe hypoglycaemia in diabetic patients....
Bayer begins Phase III programme of vilaprisan to treat uterine fibroids
Bayer has started a Phase III ASTEROID clinical programme of vilaprisan with enrolment of the first patient for treatment of uterine...
Daiichi Sankyo reports top-line results from Phase III trials of mirogabalin
Japanese pharmaceutical firm Daiichi Sankyo has reported top-line results from its Phase III NEUCOURSE and ALDAY clinical trials of mirogabalin to treat post-herpetic neuralgia and...
Aerpio starts dosing in Phase IIb trial of diabetic retinopathy drug
US-based Aerpio Pharmaceuticals has started dosing patients in the Phase IIb (TIME-2b) clinical trial of its product candidate AKB-9778, which could be used to treat patients with...
eTheRNA initiates Phase Ib trial of TriMix-MEL for metastatic melanoma
NIAID-funded trial shows use of common antimicrobials for MRSA abscesses
A clinical trial funded by the National Institute of Allergy and Infectious Diseases' (NIAID) health division has demonstrated the use of common and inexpensive antimicrobials to heal...
CytomX starts dosing in Phase I/II trial of CX-2009 to treat solid tumours
US-based biopharmaceutical firm CytomX Therapeutics has started dosing patients in a Phase I/II clinical trial (PROCLAIM CX-2009) of CX-2009 for the treatment of patients with select advanced...
AstraZeneca and Chi-Med begin Phase III trial of savolitinib for PRCC
AstraZeneca and Hutchison China MediTech (Chi-Med) have started a Phase III SAVOIR clinical trial of savolitinib to treat patients with papillary renal cell carcinoma (PRCC)....
